English | Español

Biospace
+ Pharmaceuticals
Patient Daily | Feb 4, 2026

Lilly and Repertoire partner on T cell therapies in $1.9B autoimmune disease deal
+ Pharmaceuticals
Patient Daily | Feb 4, 2026

AstraZeneca announces $15 billion investment plan for cell therapies and manufacturing in China
+ Pharmaceuticals
Patient Daily | Feb 4, 2026

Sanofi sees dip in vaccine sales amid US policy changes but forecasts growth
+ Pharmaceuticals
Patient Daily | Feb 4, 2026

Roche targets third place in global obesity drug market after acquisitions
+ Pharmaceuticals
Patient Daily | Feb 4, 2026

Biotech investors focus on asset-centric deals amid shifting risks after JPM 2026
+ Pharmaceuticals
Patient Daily | Feb 4, 2026

Biotech IPO boom of 2021 faces reality check as sector recalibrates
+ Pharmaceuticals
Patient Daily | Feb 4, 2026

Moderna partners with Recordati on rare disease mRNA therapy worth up to $160 million
+ Pharmaceuticals
Patient Daily | Feb 4, 2026

Summit Therapeutics’ ivonescimab faces key FDA decision as potential Keytruda competitor

Trending
+ Pharmaceuticals
Patient Daily | Aug 6, 2026

FDA approves Replimune’s melanoma drug Tudriqev after advisory committee debate
+ Pharmaceuticals
Patient Daily | Aug 4, 2026

Merck reports mixed results for tulisokibart in recent clinical trials and financial update
+ Regulatory
M. Y. Bailey | Aug 7, 2026

PhRMA's Zirkelbach: 340B program has changed dramatically with 'little transparency into how patients benefit'
Patient Daily reports | Aug 10, 2026

SoCal Breathe Free warns persistent sinus symptoms may signal chronic inflammation